Dr Reddy's introduces Aripiprazole, USP tablets in US market; stock down 1.04%

Dr Reddy's launched Aripiprazole and USP tablets in the United States (US) market on Thursday. 

"...The company has launched Aripiprazole tablets, USP, in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, a therapeutic equivalent generic version of Abilify (Aripiprazole) tablets in the US market approved by the US Food and Drug Administration (USFDA)," Dr Reddy's Laboratories said in a filing to the BSE on Thursday. 

According to IMS Health data, the Abilify brand and generic tablets had US sales of approximately $3.1 billion (nearly Rs 20,623.53 crore) MAT for the most recent twelve months ending in August 2016, it further said in a filing. 

The company's Aripiprazole tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg and 30 mg are available in bottle count sizes of 30. 

Abilify is a registered trademark of Otsuka Pharmaceutical company.

See LIVE stock updates of Dr Reddy's here-

At 12:20 hours, the stock of Dr Reddy's was trading down 1.04% or Rs 32.05 at Rs 3,046.00 on the BSE.